Development of a risk score for predicting the benefit versus harm of extending dual antiplatelet therapy beyond 6 months following percutaneous coronary intervention for stable coronary artery disease.
Guy WitbergYgal PlakhtTamir BentalBecca S FeldmanMaya Leventer-RobertsAmos LeviHagit GabayRan BalicerYariv GerberRan KornowskiPublished in: PloS one (2019)
In a population of SCAD patients who completed 6 months of DAPT, a risk score for subsequent ischaemic and bleeding events identified patients likely to benefit from continuing or stopping DAPT.
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- coronary artery disease
- acute coronary syndrome
- st segment elevation myocardial infarction
- acute myocardial infarction
- st elevation myocardial infarction
- coronary artery bypass grafting
- atrial fibrillation
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- coronary artery bypass
- peritoneal dialysis
- prognostic factors
- cardiovascular disease
- cardiovascular events
- heart failure
- type diabetes
- patient reported